UBS analyst Ashwani Verma lowered the firm’s price target on Legend Biotech (LEGN) to $48 from $54 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech highlights new CARVYKTI data in RRMM
- H.C. Wainwright says Legend Biotech competition concerns overdone
- Buy Rating for Legend Biotech Reaffirmed Due to CARVYKTI’s Strong Market Position and Proven Efficacy
- Legend Biotech price target raised to $75 from $66 at Cantor Fitzgerald
- Legend Biotech price target lowered to $90 from $94 at Barclays